Skip to content

The effect of vitamin E on stroke-associated pneumonia

The effect of vitamin E on stroke-associated pneumonia

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026362
Enrollment
Unknown
Registered
2019-10-03
Start date
2019-10-01
Completion date
Unknown
Last updated
2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke-associated pneumonia

Interventions

A2:Vitamin E administered via gastric tube 50mg/d
A3:Vitamin E administered via gastric tube 100mg/d
B2:Vitamin E administered via gastric tube 50mg/d
B3:Vitamin E administered via gastric tube 100mg/d
C2:Vitamin E administered via gastric tube 50mg/d
C3:Vitamin E administered via gastric tube 100mg/d
normal nutrition group (A)1:placebo
nutrition risk group (B) 2:placebo
malnutrition group (C)1:placebo

Sponsors

Qingdao Municipal Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
61 Years to 75 Years

Inclusion criteria

Inclusion criteria: Fever with a body temperature more than 37 degree C; peripheral white blood cell count greater than 10x10^9 /L, with or without nuclear left shift; new cough, respiratory purulent secretions, with or without chest pain; sputum bacteria smear or culture finding of pathogenic bacteria; or chest X-ray examination finding of new or progressive pulmonary exudation, change, cavity or pleura exudation.

Exclusion criteria

Exclusion criteria: Transient ischaemic attack (TIA); stroke onset more than 72 hours prior to admission, less than 24 hours after admission, or death; clinical symptoms of pulmonary infectious diseases (such as tuberculosis, lung cancer, severe heart failure, pulmonary oedema, pulmonary embolism, pulmonary atelectasis or infection, or interstitial lung disease); multidrug-resistant bacterial infection; hepatorenal failure or end-stage chronic consumptive disease; Glasgow score of less than 8 points in coma patients; blood, plasma, or albumin transfusion within 1 month before admission; definite chronic bronchitis and lung infection before disease onset; and serious diseases of the heart, liver, kidney, lung and other important organs.

Design outcomes

Primary

MeasureTime frame
CD47, CD55;

Countries

China

Contacts

Public ContactShen Hongwei

Qingdao Municipal Hospital

byz99996@sina.com+86 15610069312

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026